Select therapeutic use:

Bladder, kidney, and other urologic cancers:

Indications for OPDIVO:

As a single agent for treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. In combination with ipilimumab in patients with intermediate or poor risk, previously untreated advanced RCC. Locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Adult:

Give as IV infusion over 30mins. ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks until disease progression or unacceptable toxicity. In combination with ipilimumab: 3mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks (as single agent) until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx

Colorectal and other GI cancers:

Indications for OPDIVO:

As a single agent or in combination with ipilimumab for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) in patients ≥12yrs who has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. As a single agent or in combination with ipilimumab for the treatment of hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine and platinum-based chemotherapy.

Adult:

Give as IV infusion over 30mins. Continue until disease progression or unacceptable toxicity. CRC: ≥12yrs: Single-agent (≥40kg): 240mg every 2 weeks or 480mg every 4 weeks; (<40kg): 3mg/kg every 2 weeks. In combination with ipilimumab: 3mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks (≥40kg) or 3mg/kg every 2 weeks (<40kg) as single agent. HCC: ≥18yrs: Single-agent: 240mg every 2 weeks or 480mg every 4 weeks. In combination with ipilimumab: 1mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks as single agent. ESCC: ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks. Dose modifications: see full labeling.

Children:

CRC: <12yrs: not established. HCC, ESCC: <18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx

Head and neck cancer:

Indications for OPDIVO:

Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

Adult:

Give as IV infusion over 30mins. ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx

Leukemias, lymphomas, and other hematologic cancers:

Indications for OPDIVO:

Classical Hodgkin lymphoma (cHL) that relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or after 3 or more lines of systemic therapy that includes autologous HSCT.

Adult:

Give as IV infusion over 30mins. ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx

Melanoma and other skin cancers:

Indications for OPDIVO:

As a single agent or in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. Adjuvant treatment for melanoma in patients with involvement of lymph nodes or metastatic disease who have undergone complete resection.

Adult:

Give as an IV infusion over 30mins. ≥18yrs: Single agent: 240mg every 2 weeks or 480mg every 4 weeks until disease progression or unacceptable toxicity. In combination with ipilimumab: 1mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks (as single agent) until disease progression or unacceptable toxicity. Adjuvant: 240mg every 2 weeks or 480mg every 4 weeks until disease recurrence or unacceptable toxicity for up to 1 year. Dose modifications: see full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx

Respiratory and thoracic cancers:

Indications for OPDIVO:

In combination with ipilimumab for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 (≥1%) with no EGFR or ALK genomic tumor aberrations, as determined by an FDA-approved test. In combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for first-line treatment of metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. Metastatic NSCLC with progression on or after platinum-based chemotherapy. Metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.

Adult:

Give as IV infusion over 30mins. ≥18yrs: NSCLC with PD-L1: 3mg/kg every 2 weeks with ipilimumab (1mg/kg every 6 weeks); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. Metastatic or recurrent NSCLC: 360mg every 3 weeks with ipilimumab (1mg/kg every 6 weeks) and histology-based platinum doublet chemotherapy every 3 weeks (for 2 cycles only); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. NSCLC (single-agent): 240mg every 2 weeks or 480mg every 4 weeks until disease progression or unacceptable toxicity. SCLC: 240mg every 2 weeks until disease progression or unacceptable toxicity. Combination therapy: administer Opdivo first followed by ipilimumab, and/or platinum doublet chemotherapy on the same day. Dose modifications: see full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

See full labeling. Monitor for any immune-mediated adverse reactions; permanently discontinue or withhold, and give corticosteroids (at 1–2mg/kg/day prednisone equivalents) based on severity of event. Permanently discontinue for any life-threatening (Grade 4) adverse reaction, Grade 3 or 4 pneumonitis, Grade 3 or 4 or recurrent colitis (with ipilimumab), Grade 4 or recurrent colitis (as single agent), AST/ALT >5×ULN (non-HCC) or AST/ALT >10×ULN (HCC) or total bilirubin >3×ULN, SCr >6×ULN, Grade 4 hypophysitis, Grade 3 or 4 adrenal insufficiency, Grade 4 hyperglycemia, Grade 4 rash (or confirmed SJS or TEN), immune-mediated encephalitis, recurring Grade 3 adverse reactions, Grade 3 myocarditis, requirement for ≥10mg/day prednisone (or equivalent) for >12 weeks, or persistent Grade 2 or 3 adverse reactions lasting ≥12 weeks. Grade 2 pneumonitis, Grade 2 or 3 (as single agent) colitis, elevations in AST/ALT or bilirubin from baseline (see full labeling), SCr >1.5–6×ULN, Grade 2 or 3 hypophysitis, Grade 2 adrenal insufficiency, Grade 3 hyperglycemia, Grade 3 rash (or suspected SJS or TEN), new onset moderate to severe neurologic symptoms, other Grade 3 adverse reactions (1st occurrence); withhold dose, give corticosteroids, and resume when return to Grade 0 or 1. Interrupt or decrease infusion rate if mild or moderate infusion reactions occur; discontinue if severe or life-threatening. Monitor for abnormal liver tests, elevated serum creatinine, hyperglycemia, and thyroid function prior to and during treatment; give replacement therapy for hypothyroidism. Monitor for allogeneic HSCT-related complications (eg, hyperacute, acute or chronic GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease) and treat promptly. Evaluate for Vogt-Koyanagi-Harada-like syndrome if uveitis in combination with other immune-mediated reactions occur. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy (esp. during 2nd & 3rd trimesters): avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after the last dose).

Pharmacologic Class:

Human programmed death receptor-1 (PD-1)-blocking antibody.

Interactions:

Increased mortality when nivolumab is added to thalidomide analogue plus dexamethasone regimen in multiple myeloma: not recommended.

Adverse Reactions:

Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper RTI, pyrexia, headache, abdominal pain, vomiting; also with ipilimumab: hypothyroidism, decreased weight, dizziness; immune-mediated reactions (may be fatal).

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 10mL, 24mL)—1

Pricing for OPDIVO

24ml of 240mg/24ml vial (Qty: 1)
Appx. price $6722
GoodRx